|
|
|
Company Name
|
GlaxoSmithKline PLC
|
|
Drug Name
|
Raxibacumab (BLA resubmission)
|
|
Event Name
|
FDA decision on Raxibacumab for treating inhalational anthrax
|
|
Event Date
|
12/15/2012
|
|
Outcome
|
FDA approved Raxibacumab for inhalational anthrax on Dec.14,2012
|
|
Drug Status
|
|
|
Rival Drugs
|
|
|
Market Potential
|
|
|
Other Approvals
|
Raxibacumab BLA was resubmitted by Human Genome Sciences, which was acquired by GlaxoSmithKline in July of 2012
|
|
News |
|
|
|
Return to FDA Calendar
|